429 related articles for article (PubMed ID: 7593819)
1. Cell proliferation markers in predicting metastases in malignant melanoma.
Reddy VB; Gattuso P; Aranha G; Carson HJ
J Cutan Pathol; 1995 Jun; 22(3):248-51. PubMed ID: 7593819
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
[TBL] [Abstract][Full Text] [Related]
3. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma.
Böni R; Doguoglu A; Burg G; Müller B; Dummer R
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):416-8. PubMed ID: 8784279
[TBL] [Abstract][Full Text] [Related]
4. p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival.
Karjalainen JM; Eskelinen MJ; Kellokoski JK; Reinikainen M; Alhava EM; Kosma VM
Br J Cancer; 1999 Feb; 79(5-6):895-902. PubMed ID: 10070887
[TBL] [Abstract][Full Text] [Related]
5. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma.
Hieken TJ; Ronan SG; Farolan M; Shilkaitis AL; Das Gupta TK
Cancer; 1999 Jan; 85(2):375-82. PubMed ID: 10023705
[TBL] [Abstract][Full Text] [Related]
6. Nuclear morphometry of MIB-1 positive and negative tumor cells in primary and metastatic malignant melanoma of the skin.
Karbowniczek M; Chosia M; Domagała W
Pol J Pathol; 1999; 50(4):235-41. PubMed ID: 10721263
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma.
Barrett TL; Smith KJ; Hodge JJ; Butler R; Hall FW; Skelton HG
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):430-7. PubMed ID: 9308559
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical study of 49 cutaneous melanomas: p53, PCNA, Bcl-2 expression and multidrug resistance.
Loggini B; Rinaldi I; Pingitore R; Cristofani R; Castagna M; Barachini P
Tumori; 2001; 87(3):179-86. PubMed ID: 11504374
[TBL] [Abstract][Full Text] [Related]
9. Correlations of Ki-67 and PCNA to DNA ploidy, S-phase fraction and survival in uveal melanoma.
Karlsson M; Boeryd B; Carstensen J; Frånlund B; Gustafsson B; Kågedal B; Sun XF; Wingren S
Eur J Cancer; 1996 Feb; 32A(2):357-62. PubMed ID: 8664054
[TBL] [Abstract][Full Text] [Related]
10. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin.
Vogt T; Zipperer KH; Vogt A; Hölzel D; Landthaler M; Stolz W
Histopathology; 1997 Jan; 30(1):57-63. PubMed ID: 9023558
[TBL] [Abstract][Full Text] [Related]
11. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors.
Gelsleichter L; Gown AM; Zarbo RJ; Wang E; Coltrera MD
Mod Pathol; 1995 Jun; 8(5):530-5. PubMed ID: 7675773
[TBL] [Abstract][Full Text] [Related]
12. Proliferating cell nuclear antigen (PCNA) and recurrence in patients with cutaneous melanoma.
Vecchiato A; Rossi CR; Montesco MC; Frizzera E; Seno A; Piccoli A; Martello T; Ninfo V; Lise M
Melanoma Res; 1994 Aug; 4(4):207-11. PubMed ID: 7950356
[TBL] [Abstract][Full Text] [Related]
13. Transformation in recurrent ovarian granulosa cell tumors: Ki67 (MIB-1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior.
Costa MJ; Walls J; Ames P; Roth LM
Hum Pathol; 1996 Mar; 27(3):274-81. PubMed ID: 8600043
[TBL] [Abstract][Full Text] [Related]
14. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
15. p53 and PCNA expression in malignant melanomas of the head and neck.
Girod SC; Groth W; Junk M; Gerlach KL
Pigment Cell Res; 1994 Oct; 7(5):354-7. PubMed ID: 7886008
[TBL] [Abstract][Full Text] [Related]
16. Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study.
Niezabitowski A; Czajecki K; Ryś J; Kruczak A; Gruchała A; Wasilewska A; Lackowska B; Sokołowski A; Szklarski W
J Surg Oncol; 1999 Mar; 70(3):150-60. PubMed ID: 10102344
[TBL] [Abstract][Full Text] [Related]
17. A comparison of cellular proliferation markers in squamous cell carcinoma of the head and neck.
Jones AS; Roland NJ; Caslin AW; Cooke TG; Cooke LD; Forster G
J Laryngol Otol; 1994 Oct; 108(10):859-64. PubMed ID: 7989834
[TBL] [Abstract][Full Text] [Related]
18. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic factors in thin cutaneous malignant melanoma].
Massi D; Franchi A; Santucci M
Pathologica; 2002 Dec; 94(6):282-9. PubMed ID: 12540991
[TBL] [Abstract][Full Text] [Related]
20. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins.
Amada S; Nakano H; Tsuneyoshi M
Int J Gynecol Pathol; 1995 Apr; 14(2):134-42. PubMed ID: 8601525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
